US › Healthcare

CytoMed Therapeutics Limited Ordinary Shares (GDTC)

US · Healthcare · Biotechnology

$0.88+1.15%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$157,673

Revenue YoY

+17.0%

Net profit

$-1.8M

Net margin

-1,125.6%

Key statistics

Market cap

$10.4M

Forward P/E

0.0

P/B

2.10

Book value

$0.33

EPS (TTM)

$-0.23

52-week high

$3.68

52-week low

$0.68

50-day MA

$0.90

200-day MA

$1.01

Beta

0.07

Analyst view

Analysts rate CytoMed Therapeutics Limited Ordinary Shares a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.16.

Shareholding

Insiders

69.87%

Institutions

0.14%

Largest institutional holders

Fund	Stake
Axiom Investment Management LLC	0.06%
UBS Group AG	0.04%
Advisor Group Holdings, Inc.	0.00%
StoneX Group Inc	0.00%
XTX Topco Ltd	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CytoMed Therapeutics Limited Ordinary Shares — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.